- 1 Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in samples from
- 2 vaccinated individuals
- 3
- 4 Johannes Hayer¹
- 5 Eva Urlaub¹
- 6
- 7 ¹Roche Diagnostics GmbH, Mannheim, Germany
- 8 Corresponding author: Eva Urlaub, Roche Diagnostics GmbH, Mannheim, Germany,
- 9 <u>eva.urlaub@roche.com</u>
- 10

11 Running title

12 SARS-CoV-2 rapid POC antibody test in a vaccinated cohort

13

15 Abstract

16 Objective

- 17 The study aimed to establish the performance of the SARS-CoV-2 Rapid Antibody
- 18 Test (IgG and IgM) and the Elecsys[®] Anti-SARS-CoV-2 S assay in vaccinated
- 19 individuals.
- 20 Methods

21 A panel of serum samples from Boca Biolistics was utilized to assess antibodies

following vaccination, consisting of samples drawn prior to vaccination, after the first

- dose, or at least 14 days after the second dose of Moderna mRNA-1273 or Pfizer-
- 24 BioNTech BNT162b2 COVID-19 vaccines. Agreement between the two methods
- 25 was measured and stratified by test evaluator and assay lot.
- 26 Results
- 27 Agreement between the SARS-CoV-2 Rapid Antibody Test (IgG) and Elecsys Anti-

28 SARS-CoV-2 S assay qualitative measurements at the different assessment points

for both mRNA-1273 and BNT162b2 ranged between 97.06% (95% confidence

30 interval [CI] 84.67, 99.93) to 100% (95% CI 82.35, 100). Agreement of the SARS-

31 CoV-2 Rapid Antibody Test (IgG) with the Elecsys Anti-SARS-CoV-2 S assay was

- 32 not highly influenced by either lot or evaluator. There was a medium-to-strong
- 33 correlation between the semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgG)
- 34 result and quantitative Elecsys Anti-SARS-CoV-2 S assay in samples taken after
- both doses of the vaccines, with higher intensity bands being associated with higher

total anti-S antibody titer (mRNA-1273, p=0.0019; BNT162b2, p<0.0001).

37 Conclusion

38	Semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgG) and quantitative Elecsys
39	Anti-SARS-CoV-2 S assay correlated well, suggesting that the SARS-CoV-2 Rapid
40	Antibody Test (IgG) is helpful in understanding the immune response post-
41	vaccination. The current data support the use of the SARS-CoV-2 Rapid Antibody
42	Test (IgG) in the vaccinated population.

43 Importance

- 44 Serologic assays are an essential tool for seroprevalence surveys, for quality control
- 45 of vaccines, and to determine the response to vaccination. Although a correlate of
- 46 immunity has not yet been established for COVID-19 vaccines, antibody titers after
- 47 natural infection and vaccination have been associated with protection from
- 48 symptomatic SARS-CoV-2 infection. Rapid point-of-care assays can be of use in this
- 49 context with advantages over centralized testing, such as speed and ease of use.
- 50 The point-of-care SARS-CoV-2 Rapid Antibody Test (IgG) compared favorably to the
- 51 Elecsys Anti-SARS-CoV-2 S assay with agreement rates above 97.06%, after one or
- 52 two doses of Moderna mRNA-1273 or Pfizer-BioNTech BNT162b2. Semi-
- 53 quantitative SARS-CoV-2 Rapid Antibody Test (IgG) and quantitative Elecsys Anti-
- 54 SARS-CoV-2 S assay results correlated well, suggesting that SARS-CoV-2 Rapid
- 55 Antibody Test (IgG) is helpful in understanding the immune response post-
- vaccination. The current data support the use of the SARS-CoV-2 Rapid Antibody
- 57 Test (IgG) in the vaccinated population.

58 Keywords

- antibodies, neutralizing; COVID-19 vaccines; immunity; immunoassay; nucleocapsid
- 60 protein; point-of-care systems; SARS-CoV-2; spike protein

62 Introduction

63	Serologic immunoassays are vital in the global management of the COVID-19
64	pandemic. Measurement of antibodies to SARS-CoV-2 is important for improving
65	disease management, and accurate tests, with validated sensitivity and specificity,
66	are essential for obtaining reliable results when monitoring the pandemic via
67	seroprevalence surveys (1). Serologic assays can provide evidence of recent or past
68	infection (2), and identify those individuals still at risk of infection (3).
69	Infection with SARS-CoV-2 elicits a strong neutralizing antibody response (4), and
70	antibodies that bind via the spike protein act as neutralizing antibodies (5, 6). Several
71	studies have shown good correlation between anti-S antibodies and functional virus
72	neutralization (7–11). Neutralization assays utilizing live virus require biosafety level
73	3 containment, which can be labor intensive and low throughput (12-14); therefore
74	anti-S immunoassays, as a surrogate for neutralization, have an important role to
75	play (13, 15). On an individual patient level, anti-S immunoassays can confirm
76	vaccination status or inform upon the need for booster doses (16), which may be
77	helpful for both social and medical reasons.
78	Moderna mRNA-1273 (spikevax [™]) and Pfizer-BioNTech BNT162b2 (COMIRNATY [®])
79	COVID-19 vaccines are mRNA vaccines, approved under the U.S. Food and Drug
80	Administration's emergency use authorization, each employing a two-dose regimen
81	(17, 18). The immune response involves B cells that produce binding and
82	neutralizing antibodies against the SARS-CoV-2 S protein (19, 20) and both
83	vaccines encode the SARS-CoV-2 spike protein to generate an immune response.
84	Serologic assays are an essential tool in vaccine quality control, being used to
85	determine the response to vaccination and providing insight into the antibody
86	response from the individual patient perspective (21, 22).

87	The Elecsys [®] Anti-SARS-CoV-2 S assay (Roche Diagnostics International Ltd,
88	Rotkreuz, Switzerland) is an electrochemiluminescence immunoassay (ECLIA),
89	which has been developed for quantitative in vitro detection of antibodies in human
90	serum and plasma (23). The assay detects total antibodies, including
91	immunoglobulin G (IgG), against the receptor binding domain (RBD) of the SARS-
92	CoV-2 spike protein, and is intended for use on the fully automated and high-
93	throughput cobas e analyzers (23). The assay has been shown to detect anti-S
94	antibodies across a variety of different populations (2, 24), and has been utilized as a
95	surrogate of neutralization activity (11, 25).
96	The SARS-CoV-2 Rapid Antibody Test (Roche Diagnostics International Ltd,
97	Rotkreuz, Switzerland) is CE-marked rapid chromatographic immunoassay intended
98	for the qualitative in vitro detection of both IgM and IgG antibodies to SARS-CoV-2
99	spike or nucleocapsid proteins in human serum, plasma or whole blood, for
100	professional use in the laboratory and at point-of-care (26). A study utilizing real-
101	world clinical samples in unvaccinated individuals demonstrated that the SARS-CoV-
102	2 Rapid Antibody Test had comparable performance with the Elecsys Anti-SARS-
103	CoV-2 assay that targets the nucleocapsid protein (27).
104	The objective of this study was to establish the performance of the SARS-CoV-2
105	Rapid Antibody Test and the Elecsys Anti-SARS-CoV-2 S assay in serum samples
106	obtained from individuals who had received a COVID-19 vaccination.
107	Materials and Methods

- 108 Study design
- 109 The study was a retrospective performance study conducted at Roche Diagnostics
- 110 GmbH (Mannheim, Germany). All samples were analyzed with the SARS-CoV-2

111 Rapid Antibody Test and compared with the Elecsys Anti-SARS-CoV-2 S assay.

112 Tests were conducted as per manufacturer's instructions (23).

113 Samples

114 To assess antibodies following vaccination, a post-vaccination panel was prepared

using 74 serum samples obtained from Boca Biolistics (Florida, USA), collected

116 between February and April 2021, and stored at -20°C or colder (all available

117 samples at the time of request). Serum samples were from individuals from the USA

sampled prior to vaccination, after the first dose, or at least 14 days after the second

dose of Moderna mRNA-1273 or Pfizer-BioNTech BNT162b2 (Supplemental Table

120 1).

121 Samples were separated into aliquots of 50 µL for the SARS-CoV-2 Rapid Antibody

122 Test measurement and 200 µL for the Elecsys Anti-SARS-CoV-2 S reference

123 measurement on the cobas[®] 6000 and stored at -80°C until use.

124 An in-house panel of 15 negative serum samples, previously determined negative by

125 Elecsys Anti-SARS-CoV-2 S assay, was utilized to assess the specificity of the

126 SARS-CoV-2 Rapid Antibody Test. Samples were collected in June 2021 as part of

127 an in-house blood donation service at Roche Diagnostics (Mannheim, Germany),

anonymized, and stored at -80°C until use. No information about vaccination status

129 was available. Evaluators were blinded as to the origin of the samples. Cross-

reactivity to other pathogens was not analyzed in this study as this has been

131 evaluated elsewhere (26, 27).

132 SARS-CoV-2 Rapid Antibody Test

133 The SARS-CoV-2 Rapid Antibody Test detects the presence of SARS-CoV-2 IgM

and IgG antibodies, and the intensity of the test line is dependent upon the level of

SARS-CoV-2 antibodies present in the sample (26). In unvaccinated individuals, the
reported sensitivity is 92.59% (7–14 days post-symptom onset [POS]) and 99.03%
(>14 days POS), with specificity of 98.65% (26).

138 Each sample was tested with two different lots of the SARS-CoV-2 Rapid Antibody 139 Test. The readout was visually assessed at 10 minutes by two different independent 140 evaluators; these evaluators were not the operators who had performed the test. In 141 accordance with manufacturer's instructions, the sample was considered positive if 142 the control line and at least one colored band/test line at G or M became apparent 143 (qualitative determination). As an exploratory analysis, results were further defined 144 by the intensity of the band to provide semi-quantitative data (Supplemental Table 145 2), with the signal intensity being rated according to a color scale. Data are 146 presented separated by lot and by evaluator. In the event of an invalid result, the test 147 would be repeated.

148 Elecsys Anti-SARS-CoV-2 S assay

149 The Elecsys Anti-SARS-CoV-2 S assay results are reported automatically as the

analyte concentration of each sample in U/mL, with <0.80 U/mL interpreted as

151 negative and ≥0.80 U/mL interpreted as positive for anti-SARS-CoV-2 S antibodies

152 (23). The reported sensitivity and specificity of this test 14 days post-PCR is 97.92%

and 99.95%, respectively (24). The quantification range is between 0.4 and 250

154 U/mL and the reported limit of detection is 0.35 U/mL (23). If the sample

155 concentration is >250 U/mL, the sample can be diluted up to 1:100; in these cases,

the final result is determined as >25,000 U/mL (23).

In the event of an invalid result, the test would be repeated. All samples weremeasured in duplicate, and the result calculated as the arithmetic mean of both

replicates. Assessors were blinded to the SARS-CoV-2 Rapid Antibody Test results

- and blinded as to the origin of the samples.
- 161 Statistical analysis
- 162 The agreement rates comparing the SARS-CoV-2 Rapid Antibody Test with Elecsys
- 163 Anti-SARS-CoV-2 S assay per vaccine type were calculated per lot. Two-sided 95%
- 164 Clopper–Pearson confidence intervals (CI) for the agreement rates are given.
- 165 Correlation between the semi-quantitative SARS-CoV-2 Rapid Antibody Test data
- and quantitative Elecsys Anti-SARS-CoV-2 S assay data was assessed using the
- 167 Kendall's rank correlation D. Accuracy of the SARS-CoV-2 Rapid Antibody Test result
- 168 how often do the qualitative results agree with one another was assessed by
- 169 lot and evaluator. Statistical analyses were conducted using R (version 3.6.3) and

170 JMP (version 15).

171 Results

- 172 Overall, the study cohort consisted of 56 predominantly white/Caucasian individuals
- 173 (median age 70 years; 55.36% female) with a variety of pre-existing medical

174 conditions (Table 1). No invalid results were generated using either test.

175 Analyses of the SARS-CoV-2 Rapid Antibody Test (qualitative) with the Elecsys Anti-

- 176 SARS-CoV-2 S assay (quantitative and qualitative)
- 177 Eight samples were obtained from patients who were sampled prior to vaccination.
- 178 Whilst only two patients were reported to have been previously diagnosed with
- 179 COVID-19, only one patient was IgG and IgM negative (by both the SARS-CoV-2
- 180 Rapid Antibody Test and Elecsys Anti-SARS-CoV-2 S assay). For the seven positive
- 181 samples, Elecsys Anti-SARS-CoV-2 S total antibody titers ranged from 254.0 U/mL

to >25,000 U/mL and all were identified as positive by the SARS-CoV-2 Rapid

183 Antibody Test.

184	The post-vaccination antibody analysis included 25 samples from individuals
185	vaccinated with mRNA-1273 and 42 vaccinated with BNT162b2. The dosing interval
186	between first and second vaccine doses for BNT162b2 was a median of 21 days
187	(minimum 19 days, maximum 23 days) and a median of 28 days (minimum 21 days,
188	maximum 32 days) for mRNA-1273. There was good agreement between the SARS-
189	CoV-2 Rapid Antibody Test (IgG) and Elecsys Anti-SARS-CoV-2 S qualitative
190	measurements at the different assessment points for both the Moderna and Pfizer-
191	BioNTech vaccines ranging from 97.06% (95% CI 84.67, 99.93) to 100% (95% CI
192	89.72, 100) (Table 2). There was one false-negative sample with evaluator 2 (after
193	second dose of BNT162b2, lot 1 and lot 2), however this sample was classified as
194	positive by evaluator 1.
195	There was poor agreement between the SARS-CoV-2 Rapid Antibody Test (IgM)
196	and Elecsys Anti-SARS-CoV-2 S assay qualitative measurements at the different
197	assessment points for both BNT162b2 and mRNA-1273 ranging from 14.71% (95%
198	CI 4.95, 31.06) to 80.00% (95% CI 28.36, 99.49) with many false-negatives (Table
199	2).
200	Using the in-house negative panel, there were no false-positive results for either lot

- 201 or evaluator (Error! Reference source not found.).
- 202 Analyses of the SARS-CoV-2 Rapid Antibody Test (semi-quantitative) with the
- 203 Elecsys Anti-SARS-CoV-2 S assay (quantitative)

204 There was a medium-to-strong correlation between the semi-quantitative SARS-

205 CoV-2 Rapid Antibody Test (IgG) and quantitative Elecsys Anti-SARS-CoV-2 S

206	assay in samples taken after both doses of the vaccines (Figure 1), with higher
207	intensity bands being associated with higher total anti-S antibody titer (with Kendall's
208	I up to 0.599 for IgG mRNA-1273 [p=0.0019] and 0.6833 [p<0.0001] for IgG
209	BNT162b2) (Error! Reference source not found.). There was no correlation
210	between the quantitative Elecsys Anti-SARS-CoV-2 S assay result and the intensity
211	of the SARS-CoV-2 Rapid Antibody Test (IgM) (Error! Reference source not
212	found.).
213	Agreement between the semi-quantitative SARS-CoV-2 Rapid Antibody Test (IgM)
214	and quantitative Elecsys Anti-SARS-CoV-2 S assay was poor, with many samples
215	designated as negative on the SARS-CoV-2 Rapid Antibody Test (IgM) even in the
216	presence of high anti-S antibody titers (Results from the SARS-CoV-2 Rapid
217	Antibody Test were classified as negative or one of the five levels of increasing
218	positivity based upon line intensity (((+)), (+), +, ++ or +++). Maximum value
219	attainable by the Elecsys Anti-SARS-CoV-2 assay was 25,000 U/mL. Higher values
220	are indicated as >25,000 U/mL. Blue = Lot 1; red = Lot 2; \circ = Evaluator 1; + =
221	Evaluator 2.

223 Figure 2).

224 Accuracy of the SARS-CoV-2 Rapid Antibody Test

- 225 Comparison of the SARS-CoV-2 Rapid Antibody Test (IgG) results by lot or
- evaluator revealed that these factors did not influence the results, with a minimum
- accuracy estimate of 97.06% (Error! Reference source not found.).
- 228 SARS-CoV-2 Rapid Antibody Test (IgM) positivity appeared to be influenced by
- evaluator, with a minimum accuracy estimate of 40% and considerable variability in
- 230 accuracy estimates across the different time points and vaccines (Error! Reference
- 231 source not found.).
- 232 Evaluation of Elecsys Anti-SARS-CoV-2 S assay titer post-vaccination
- 233 Antibody titers by days following final vaccination are shown in Figure 3. Following
- complete vaccination with BNT162b2 or mRNA-1273 and up to approximately 20
- 235 days, there was significant variability with both high (maximum >25,000 U/mL) and
- 236 low (minimum 238.2 U/mL for BNT162b2 and 340.2 U/mL for mRNA-1273) anti-S
- 237 titers. After 30 days, anti-S titers for both vaccines commonly declined to below
- 5,000 U/mL (overall minimum 13.53 U/mL 25 days after vaccination with BNT162b2).
- 239 The median time between final vaccination and final measurement for those
- vaccinated with BNT162b2 was 18 days (minimum 14 days, maximum 44 days) and
- 46 days (minimum 14 days, maximum 65 days) for mRNA-1273. Anti-S antibody
- titers were numerically higher in participants vaccinated mRNA-1273 (median 2,307
- U/mL; interquartile range [IQR] 872–6,845) than in those who received BNT162b2

244 (median 1,601 U/mL; IQR 467–3,131).

245 Longitudinal analysis

246	A small number of individuals had samples available from all three time points
247	(BNT162b2 cohort), allowing longitudinal evaluation of anti-S antibody titer levels; all
248	except one showed high levels of anti-S antibody titers at the first time point (prior to
249	vaccination). There was considerable variance in the effect of vaccination upon anti-
250	S antibody titers, however the greatest change was for the individual who was
251	infection-naïve (<0.4 U/mL to 1,645 U/mL following the second dose). For five out of
252	eight individuals, including those with previously diagnosed COVID-19, anti-S
253	antibody titers decreased over time despite vaccination with BNT162b2 (Error!
254	Reference source not found.).

255 Discussion

- 256 Serologic assays are an essential tool for quality control of vaccines and to
- 257 determine the response to vaccination. Although a correlate of immunity has not yet
- 258 been established for COVID-19 vaccines, antibody titers after natural infection and
- vaccination have been associated with protection from symptomatic SARS-CoV-2
- infection (28); and rapid point-of-care assays can potentially be of use in this setting
- with particular advantages over centralized testing, such as speed and ease of use.
- 262 We evaluated the use of the SARS-CoV-2 Rapid Antibody Test in vaccinated
- individuals in comparison with the Elecsys Anti-SARS-CoV-2 S assay.
- 264 Our results indicate that the Elecsys Anti-SARS-CoV-2 S assay detects anti-S
- antibodies after the first dose of both BNT162b2 and mRNA-1273, in agreement with
- 266 previous studies of the adaptive humoral response to vaccination in various
- 267 populations (21, 22, 29–33).
- 268 Whilst the performance of rapid antibody tests has been reported in unvaccinated 269 individuals (34–36), no studies have yet reported upon their use in vaccinated

270 individuals. The SARS-CoV-2 Rapid Antibody Test (IgG) compared favorably to the 271 Elecsys Anti-SARS-CoV-2 S assay with agreement rates above 97.06%, after one 272 dose and two doses, similar to what has been observed in unvaccinated individuals 273 (27). Assessment of the influence of lot or evaluator revealed that agreement of the 274 SARS-CoV-2 Rapid Antibody Test (IgG) with the Elecsys Anti-SARS-CoV-2 S assay 275 was not highly influenced by either factor, suggesting that the SARS-CoV-2 Rapid 276 Antibody Test (IgG) is robust under normal usage conditions. 277 There was low agreement of the SARS-CoV-2 Rapid Antibody Test (IgM) with the 278 Elecsys Anti-SARS-CoV-2 S assay because, in general, there is a lower sensitivity 279 for IgM compared with IgG for point-of-care lateral flow assays, as exemplified in a 280 recent analysis of healthcare workers vaccinated with the first dose of the Pfizer 281 vaccine and sampled 21–24 days thereafter (37). In addition, the Elecsys Anti-282 SARS-CoV-2 S assay preferentially detects high-affinity IgG antibodies that compete 283 with IgM antibodies (23), contributing to the lower agreement rates with IgM results. 284 In agreement with previous research on the use of lateral flow assays in 285 unvaccinated individuals (38, 39), we also report lower evaluator concordance when 286 reading IgM compared with IgG bands. Jones and colleagues found that IgM bands 287 are often weak positives (39), consistent with our data in vaccinated individuals, 288 potentially resulting in an increased likelihood of a miscall and contributing to the low 289 reader agreement. 290 The vaccines were administered in accordance with the relevant primary dosing 291 schedules, with approximately 3 weeks for BNT162b2 and 1 month for mRNA-1273 292 between doses (17, 18). Whilst the data reported herein suggest some variation in

the level of antibody titers afforded by the vaccines, two doses of either mRNA-1273

or BNT162b2 induced high levels of anti-S antibodies. Anti-S total antibody titers

295 were higher in participants vaccinated with mRNA-1273 than BNT162b2, in 296 accordance with previous publications (40). Whilst the clinical significance of 297 quantitative differences in antibody titers following COVID219 vaccination have not 298 yet been established, understanding the differences in antibody titer can support 299 individual choices and assist with policy decisions. 300 The longitudinal analysis revealed that five individuals in the BNT162b2 cohort 301 appeared to have previously undiagnosed SARS-CoV-2 infection prior to 302 vaccination, and the effect of vaccination upon anti-S antibody titers in this group at 303 the individual level was highly variable (relative decrease or increase after the first 304 dose). Overall, after primary vaccination with two doses, all except one of those with 305 previous natural infection had higher anti-S antibody titers than the infection-naïve 306 participant, in agreement with previous reports which support higher titers following 307 vaccination in previously infected individuals (40-42). 308 The findings of this study are subject to several limitations. The performance of the 309 SARS-CoV-2 Rapid Antibody Test in vaccinated individuals was based on the 310 evaluation of a relatively small panel of samples and utilized only two vaccines. 311 However, the cohort tested was generally representative of an aged US population, 312 with hypertension and diabetes mellitus in line with age-related expectations of 313 prevalence (43, 44). Whilst the median anti-S antibody titers induced by vaccination 314 differed between those vaccinated with BNT162b2 or mRNA-1273, the majority of 315 the post-vaccination BNT162b2 samples were collected earlier than samples 316 collected for mRNA-1273, there were more data points for BNT162b2, and the data 317 for mRNA-1273 samples spanned a longer time frame (last sample was post 60 318 days for mRNA-1273 compared with <45 days for BNT162b2). Furthermore, most of

the samples used in the longitudinal analysis were from positive pre-vaccinatedindividuals, which limits our findings.

321	The clinical relevance of semilguantitative results is currently unknown and, at
322	present, cannot be interpreted as an indication of varying levels of immunity. In
323	addition, semi-quantitative evaluation of the intensity of the bands is determined by
324	the reader and therefore subjective, even with the use of a color scale guide and
325	training. The performance of the SARS-CoV-2 Rapid Antibody Test seen herein can
326	also not be extrapolated to immunocompromised individuals whose immune
327	response post vaccination may be more variable (45). However, semi-quantitative
328	SARS-CoV-2 Rapid Antibody Test (IgG) and quantitative Elecsys Anti-SARS-CoV-2
329	S assay results correlated well, suggesting that SARS-CoV-2 Rapid Antibody Test
330	(IgG) is helpful in understanding the immune response post vaccination, particularly
331	in the absence of centralized and fully automated testing systems. The current data
332	support the use of the SARS-CoV-2 Rapid Antibody Test (IgG) in the vaccinated
333	population.

334 Conflicts of interest

335 All authors have completed the ICMJE uniform disclosure form at

336 <u>www.icmje.org/coi_disclosure.pdf</u> and declare: that JH and EU are employees of

- 337 Roche Diagnostics; EU participates in Roche Connect; no other relationships or
- activities that could appear to have influenced the submitted work.

339 Ethical approval and consent

- 340 Anonymized samples were provided by the commercial supplier Boca Biolistics and
- 341 collected under their ethical approval system. Ethical approval for the in-house panel
- 342 was provided by Ethik-Kommission II der Universität Heidelberg, Medizinische

343 I akuitat, iviallille illi, Gellially, Salliples were allolly illized, allo collected allo	343 Fakul	Mannneim, Germany,	. Samples were anon	iymized, and	l collected a	na testea
--	-----------	--------------------	---------------------	--------------	---------------	-----------

- in accordance with applicable regulations, including relevant European Union
- directives and regulations, and the principles of the Declaration of Helsinki.

346 **Data availability**

- 347 Qualified researchers may request access to individual anonymized patient-level
- 348 data through the clinical study data request platform (https://vivli.org/). Further details
- 349 on Roche's criteria for eligible studies are available here:
- 350 https://vivli.org/members/ourmembers/. For further details on Roche's Global Policy
- 351 on the Sharing of Clinical Information and how to request access to related clinical
- 352 study documents, see here:
- 353 https://www.roche.com/research_and_development/who_we_are_how_we_work/clin
- ical_trials/our_commitment_to_data_sharing.htm.

355 Funding

- 356 Roche Diagnostics GmbH (Mannheim, Germany) provided financial support for the
- 357 study and for preparation of the article. Roche Diagnostics GmbH was involved in
- the study design; in the collection, analysis and interpretation of data; in the writing of
- the report; and in the decision to submit the article for publication. Medical writing
- 360 support was funded by Roche Diagnostics GmbH.

361 Acknowledgements

362 Medical writing support was provided by Corrinne Segal, Elements Communications

- 363 Ltd, Westerham, UK. The authors would like to thank Rabea Held, Regina Draude,
- 364 Maureen Adamietz, Shervan Horo, and Jlenia Marconi of Roche Diagnostics for their
- 365 contribution to the study. COBAS, COBAS E, and ELECSYS are trademarks of
- 366 Roche. All other product names and trademarks are the property of their respective

- 367 owners'. The specific application (use in vaccinated individuals) is currently outside
- 368 of the intended use of the SARS-CoV-2 Rapid Antibody Test. The Elecsys Anti-
- 369 SARS-CoV-2 S assay is approved under an Emergency Use Authorization in the US.

370

372 References

- Krammer F, Simon V. 2020. Serology assays to manage COVID-19. Science
 368:1060–1061.
- 2. Riester E, Majchrzak M, Mühlbacher A, Tinguely C, Findeisen P, Hegel JK,
- Laimighofer M, Rank CM, Schönfeld K, Langen F, Laengin T, Niederhauser C.
- 377 2021. Multicentre performance evaluation of the Elecsys Anti-SARS-CoV-2
- immunoassay as an aid in determining previous exposure to SARS-CoV-2. Infect
- 379 Dis Ther doi:10.1007/s40121-021-00504-9:1–17.
- 380 3. Alter G, Seder R. 2020. The power of antibody-based surveillance. N Engl J Med
 381 383:1782–1784.
- 4. Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan WH, Chiu SS, Ko RLW,

383 Chan KH, Cheng SMS, Perera R, Cowling BJ, Poon LLM, Peiris M. 2021.

384 Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun 12:63.

- 385 5. Yang J, Petitjean SJL, Koehler M, Zhang Q, Dumitru AC, Chen W, Derclaye S,
- Vincent SP, Soumillion P, Alsteens D. 2020. Molecular interaction and inhibition
 of SARS-CoV-2 binding to the ACE2 receptor. Nat Commun 11:4541.
- 388 6. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. 2020. Structural basis for the
- recognition of SARS-CoV-2 by full-length human ACE2. Science 367:1444–1448.
- 390 7. Bal A, Pozzetto B, Trabaud MA, Escuret V, Rabilloud M, Langlois-Jacques C,
- 391 Paul A, Guibert N, D'Aubarède-Frieh C, Massardier-Pilonchery A, Fabien N,
- 392 Goncalves D, Boibieux A, Morfin-Sherpa F, Pitiot V, Gueyffier F, Lina B, Fassier
- JB, Trouillet-Assant S. 2021. Evaluation of high-throughput SARS-CoV-2

394	serological assays in a longitudinal cohort of patients with mild COVID-19: clinical
395	sensitivity, specificity, and association with virus neutralization test. Clin Chem
396	67:742–752.

- 397 8. Bonelli F, Sarasini A, Zierold C, Calleri M, Bonetti A, Vismara C, Blocki FA,
- 398 Pallavicini L, Chinali A, Campisi D, Percivalle E, DiNapoli AP, Perno CF, Baldanti
- F. 2020. Clinical and analytical performance of an automated serological test that
 identifies S1/S2-neutralizing IgG in COVID-19 patients semiguantitatively. J Clin
- 401 Microbiol 58:e01224–20.

402 9. Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, McGuire

J, Clearly S, Furrie E, Greig N, Hay G, Templeton K, Lorenzi JCC, Hatziioannou

T, Jenks S, Bieniasz PD. 2021. Longitudinal serological analysis and neutralizing
antibody levels in coronavirus disease 2019 convalescent patients. J Infect Dis
223:389–398.

Weidner L, Gänsdorfer S, Unterweger S, Weseslindtner L, Drexler C, Farcet M,
Witt V, Schistal E, Schlenke P, Kreil TR, Jungbauer C. 2020. Quantification of
SARS-CoV-2 antibodies with eight commercially available immunoassays. J Clin
Virol 129:104540.

411 11. Rubio-Acero R, Castelletti N, Fingerle V, Olbrich L, Bakuli A, Wölfel R, Girl P,

412 Müller K, Jochum S, Strobl M, Hoelscher M, Wieser A. 2021. In search of the

413 SARS-CoV-2 protection correlate: Head-to-head comparison of two quantitative

414 S1 assays in pre-characterized oligo-/asymptomatic patients. Infect Dis Ther

415 10:1505–1518.

416	12.	Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, Zhang L, Nie L, Qin H, Wang M, Lu Q,
417		Li X, Sun Q, Liu J, Fan C, Huang W, Xu M, Wang Y. 2020. Establishment and
418		validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg
419		Microbes Infect 9:680–686.
420	13.	Oguntuyo KY, Stevens CS, Hung CT, Ikegame S, Acklin JA, Kowdle SS,
421		Carmichael JC, Chiu HP, Azarm KD, Haas GD, Amanat F, Klingler J, Baine I,
422		Arinsburg S, Bandres JC, Siddiquey MNA, Schilke RM, Woolard MD, Zhang H,
423		Duty AJ, Kraus TA, Moran TM, Tortorella D, Lim JK, Gamarnik AV, Hioe CE,
424		Zolla-Pazner S, Ivanov SS, Kamil JP, Krammer F, Lee B. 2021. Quantifying
425		absolute neutralization titers against SARS-CoV-2 by standardized virus
426		neutralization assay allows for cross-cohort comparisons of COVID-19 sera.
427		mBio 12:e02492–20.
428	14.	Vanderheiden A, Edara VV, Floyd K, Kauffman RC, Mantus G, Anderson E,
429		Rouphael N, Edupuganti S, Shi PY, Menachery VD, Wrammert J, Suthar MS.
430		2020. Development of a rapid focus reduction neutralization test assay for
431		measuring SARS-CoV-2 neutralizing antibodies. Curr Protoc Immunol 131:e116.
432	15.	Jochum S, Kirste I, Hortsch S, Grunert VP, Legault H, Eichenlaub U, Kashlan B,
433		Pajon R. 2021. Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19
434		vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial. medRxiv
435		doi:10.1101/2021.10.04.21264521:2021.10.04.21264521.
436	16.	Baldanti F, Ganguly N, Wang G, Möckel M, O'Neill L, Renz H, Eduardo dos

437 Santos Ferreira C, Tateda K, Van Der Pol B. 2021. Deployment of SARS-CoV-2

438	diagnostic testing: challenges and key considerations for the future. Clin Rev Lab
439	Sci [submitted].

440	17.	Pfizer-BioNTech. 2021. Fact sheet for healthcare providers administering
441		vaccine (vaccination providers): emergency use authorization (EUA) of the
442		Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019
443		(COVID-19). https://www.fda.gov/media/153713/download. Accessed 26 Nov
444		2021.

- 18. Moderna TX. 2021. Fact sheet for healthcare providers administering vaccine
- 446 (vaccination providers): emergency use authorization (EUA) of the moderna

447 COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19).

448 https://www.fda.gov/media/144637/download. Accessed 26 Nov 2021.

449 19. Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M,

450 Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B,

Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Neuzil KM, Bennett H, Leav B,

452 Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Buchanan W,

453 Luke CJ, Ledgerwood JE, Mascola JR, Graham BS, Beigel JH. 2021. Durability

454 of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med 384:80–

455

82.

Mrak D, Tobudic S, Koblischke M, Graninger M, Radner H, Sieghart D, Hofer P,
Perkmann T, Haslacher H, Thalhammer R, Winkler S, Blüml S, Stiasny K, Aberle
JH, Smolen JS, Heinz LX, Aletaha D, Bonelli M. 2021. SARS-CoV-2 vaccination
in rituximab-treated patients: B cells promote humoral immune responses in the
presence of T-cell-mediated immunity. Ann Rheum Dis 80:1345–1350.

461	21.	Lukaszuk K, Kiewisz J, Rozanska K, Dabrowska M, Podolak A, Jakiel G,
462		Woclawek-Potocka I, Lukaszuk A, Rabalski L. 2021. Usefulness of IVD kits for
463		the assessment of SARS-CoV-2 antibodies to evaluate the humoral response to
464		vaccination. Vaccines 9:840.
465	22.	Salvagno GL, Henry BM, di Piazza G, Pighi L, De Nitto S, Bragantini D,
466		Gianfilippi GL, Lippi G. 2021. Anti-SARS-CoV-2 receptor-binding domain total
467		antibodies response in seropositive and seronegative healthcare workers
468		undergoing COVID-19 mRNA BNT162b2 Vaccination. Diagnostics 11:832.
469	23.	Roche Diagnostics. 2021. Elecsys® Anti-SARS-CoV-2 S, instructions for use
470		(09289275190, V3.0, Dec 2021).
471	24.	Riester E, Findeisen P, Hegel JK, Kabesch M, Ambrosch A, Rank CM, Pessl F,
472		Laengin T, Niederhauser C. 2021. Performance evaluation of the Roche Elecsys
473		Anti-SARS-CoV-2 S immunoassay. J Virol Methods 297:114271.
474	25.	Resman Rus K, Korva M, Knap N, Avšič Županc T, Poljak M. 2021. Performance
475		of the rapid high-throughput automated electrochemiluminescence immunoassay
476		targeting total antibodies to the SARS-CoV-2 spike protein receptor binding
477		domain in comparison to the neutralization assay. J Clin Virol 139:104820.
478	26.	Roche Diagnostics/SD BioSensor. 2020. SARS-CoV-2 Rapid Antibody Test,
479		instructions for use (9901-NCOV-02C, V2.0, Sept 2020).
480	27.	Findeisen P, Stiegler H, Lopez-Calle E, Schneider T, Urlaub E, Hayer J,
481		Zemmrich C. 2021. Clinical performance evaluation of a SARS-CoV-2 Rapid

- Antibody Test for determining past exposure to SARS-CoV-2. Int J Infect Dis
 103:636–641.
- 484 28. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao
 485 K, Kent SJ, Triccas JA, Davenport MP. 2021. Neutralizing antibody levels are
 486 highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
 487 Nat Med 27:1205–1211.
- 488 29. Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice
- 489 R, Chee D, Cummings JF, Fraser A, Irving PM, Kamperidis N, Kok KB, Lamb
- 490 CA, Macdonald J, Mehta S, Pollok RC, Raine T, Smith PJ, Verma AM, Jochum
- 491 S, McDonald TJ, Sebastian S, Lees CW, Powell N, Ahmad T. 2021. Infliximab is
- 492 associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-
- 493 19 SARS-CoV-2 vaccines in patients with IBD. Gut 70:1884–1893.
- 494 30. Callegaro A, Borleri D, Farina C, Napolitano G, Valenti D, Rizzi M, Maggiolo F.
- 495 2021. Antibody response to SARS-CoV-2 vaccination is extremely vivacious in
- 496 subjects with previous SARS-CoV-2 infection. J Med Virol 93:4612–4615.
- 497 31. Cavalcanti E, Isgrò MA, Rea D, Di Capua L, Trillò G, Russo L, Botti G, Miscio L,
- 498 Buonaguro FM, Bianchi AAM. 2021. Vaccination strategy and anti SARS-CoV-
- 499 2 S titers in healthcare workers of the INT IRCCS "Fondazione Pascale"
- 500 Cancer Center (Naples, Italy). Infect Agent Cancer 16:32.
- 32. Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, Morales M, Ziv T,
 Shorer Arbel Y, Scarfò L, Joffe E, Perry C, Ghia P. 2021. Efficacy of the

503 BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic 504 leukemia. Blood 137:3165–3173.

- 505 33. Seyahi E, Bakhdiyarli G, Oztas M, Kuskucu MA, Tok Y, Sut N, Ozcifci G,
- 506 Ozcaglayan A, Balkan, II, Saltoglu N, Tabak F, Hamuryudan V. 2021. Antibody
- 507 response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated
- diseases: a controlled study among hospital workers and elderly. Rheumatol Int41:1429–1440.
- 510 34. Batra R, Olivieri LG, Rubin D, Vallari A, Pearce S, Olivo A, Prostko J, Nebbia G,
- 511Douthwaite S, Rodgers M, Cloherty G. 2020. A comparative evaluation between512the Abbott Panbio™ COVID-19 IgG/IgM rapid test device and Abbott Architect™
- 513 SARS CoV-2 IgG assay. J Clin Virol 132:104645.
- 514 35. Naranbhai V, Chang CC, Beltran WFG, Miller TE, Astudillo MG, Villalba JA, Yang
- 515 D, Gelfand J, Bernstein BE, Feldman J, Hauser BM, Caradonna TM, Alter G,
- 516 Murali MR, Jasrasaria R, Quinlan J, Xerras DC, Betancourt JR, Louis DN,
- 517 Schmidt AG, Lennerz J, Poznansky MC, lafrate AJ. 2020. High seroprevalence
- 518 of anti-SARS-CoV-2 antibodies in Chelsea, Massachusetts. J Infect Dis
- 519 222:1955–1959.
- 520 36. Pallett SJC, Rayment M, Patel A, Fitzgerald-Smith SAM, Denny SJ, Charani E,
- 521 Mai AL, Gilmour KC, Hatcher J, Scott C, Randell P, Mughal N, Jones R, Moore
- 522 LSP, Davies GW. 2020. Point-of-care serological assays for delayed SARS-CoV-
- 523 2 case identification among health-care workers in the UK: A prospective
- 524 multicentre cohort study. Lancet Respir Med 8:885–894.

525	37.	Saluzzo F, Mantegani P, Poletti De Chaurand V, Quaresima V, Cugnata F, Di
526		Serio C, Macé A, De Vos M, Sacks JA, Cirillo DM. 2021. SARS-CoV-2 Antibody
527		Rapid Tests: Valuable Epidemiological Tools in Challenging Settings. Microbiol
528		Spectr 9:e0025021.
529	38.	Whitman JD, Hiatt J, Mowery CT, Shy BR, Yu R, Yamamoto TN, Rathore U,
530		Goldgof GM, Whitty C, Woo JM, Gallman AE, Miller TE, Levine AG, Nguyen DN,
531		Bapat S P, Balcerek J, Bylsma SA, Lyons AM, Li S, Wong AW, Gillis-Buck EM,
532		Steinhart ZB, Lee Y, Apathy R, Lipke MJ, Smith JA, Zheng T, Boothby IC, Isaza
533		E, Chan J, Acenas DD 2 nd , Lee J, Macrae TA, Kyaw TS, Wu D, Ng DL, Gu W,
534		York VA, Eskandarian HA, Callaway PC, Warrier L, Moreno ME, Levan J, Torres
535		L, Farrington LA, Loudermilk RP, Koshal K, Zorn KC, Garcia-Beltran WF, Yang
536		D, Astudillo MG, Bernstein BE, Gelfand JA, Ryan ET, Charles RC, lafrate AJ,
537		Lennerz JK, Miller S, Chiu CY, Stramer SL, Wilson MR, Manglik A, Ye CJ,
538		Krogan NJ, Anderson MS, Cyster JG, Ernst JD, Wu AHB, Lynch KL, Bern C, Hsu
539		PD, Marson A. 2020. Evaluation of SARS-CoV-2 serology assays reveals a
540		range of test performance. Nat Biotechnol 38: 1174–1183.
541	39.	Jones HE, Mulchandani R, Taylor-Phillips S, Ades AE, Shute J, Perry KR,
542		Chandra NL, Brooks T, Charlett A, Hickman M, Oliver I, Kaptoge S, Danesh J, Di
543		Angelantonio E, Wyllie D. Accuracy of four lateral flow immunoassays for anti
544		SARS-CoV-2 antibodies: a head-to-head comparative study. 2021. EBioMedicine
545		68: 103414.

547	40.	Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. 2021. Comparison of
548		SARS-CoV-2 antibody response following vaccination with BNT162b2 and
549		mRNA-1273. JAMA 326:1533–1535.
550	41.	Di Meo A, Miller JJ, Fabros A, Brinc D, Hall V, Pinzon N, Ierullo M, Ku T, Ferreira
551		VH, Kumar D, Pasic MD, Kulasingam V. 2021. Evaluation of three anti-SARS-
552		CoV-2 serologic immunoassays for post-vaccine response. J Appl Lab Med Aug
553		3:jfab087.
554	42.	Terpos E, Trougakos IP, Karalis V, Ntanasis-Stathopoulos I, Gumeni S,
555		Apostolakou F, Sklirou AD, Gavriatopoulou M, Skourti S, Kastritis E, Korompoki
556		E, Papassotiriou I, Dimopoulos MA. 2021. Kinetics of anti-SARS-CoV-2 antibody
557		responses 3 months post complete vaccination with BNT162b2; A prospective
558		study in 283 health workers. Cells 10:1942.
559	43.	Centers for Disease Control and Prevention. 2020. National diabetes statistic
560		report, 2020. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-
561		statistics-report.pdf. Accessed 24 Nov 2021.
562	44.	Ostchega R, Fyar C, Nwanko T, Nguyen D. 2020. Hypertension prevalence
563		among adults aged 18 and over: United States, 2017–2018. NCHS Data Brief
564		364:1–8.
565	45.	Lee A, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, Tay SH, Teo CB,
566		Tan BKJ, Chan YH, Sundar R, Soon YY. 2022. Efficacy of covid-19 vaccines in
567		immunocompromised patients: systematic review and meta-analysis. BMJ
568		376:e068632.

569 Tables and figures for ms

570 Table 1: Demographics of the donors from the Boca Biolistics panel

Characteristics	All	Pfizer	Moderna			
	N=56	n=34	n=22			
Male/female, %	44.64/55.36	44.12/55.88	45.45/54.55			
Median age, IQR	70 (61.75–72)	70 (63–71.75)	71 (57.25–73)			
Ethnicity, %						
Asian; Not Hispanic/Latino,	1.79	2.94	0			
Black/African American; Not Hispanic/Latino	3.57	5.88	0			
White/Caucasian; Not Hispanic/Latino	64.29	61.76	68.18			
Hispanic/Latino; Black/African American	7.14	8.82	4.55			
Hispanic/Latino; White/Caucasian	23.21	20.59	27.27			
Pre-existing medical conditions, %						
Yes/No	51.79/48.21	50.00/50.00	54.55/45.45			
Hypertension, Yes/No	60.71/39.29	35.29/64.71	54.55/45.45			

Diabetes mellitus, Yes/No	7.14/92.86	11.76/88.24	0/100	
---------------------------	------------	-------------	-------	--

572 IQR, interquartile range

Table 2: Agreement between SARS-CoV-2 Rapid Antibody Test (IgG and IgM) and Elecsys Anti-SARS-CoV-2 S assay (reference
test) qualitative measurements as measured by lot and evaluator using the Boca Biolistics donor panel, and after one dose or at
least 14 days after two doses of Moderna mRNA-1273 or Pfizer-BioNTech BNT162b2

	BNT162b2							
1 dose 2 doses 1 dose	2 doses							
Evaluator 1 Evaluator 2 Evaluator Evaluator Evaluator Evaluator Evaluator	Evaluator Evaluator							
1 2 1 2	1 2							
Lot 1 Lot 2 Lot 1 Lot 2 Lot	Lot Lot Lot							
	1 2 1 2							
lg N 5 5 5 5 19 19 19 19 8 8 8 8 8 34	34 34 34 34							
G N+ 5 5 5 19 19 19 19 7 7 7 34	34 34 34 34							
N 1* 1* 1* 1* -								
TP 5 5 5 19 19 19 7 7 7 34	34 34 33 33							
FN 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0) 0 1 1							
PPA, % 100 100 100 100 100 100 100 100 100 10	100 100 97.0 97.0							
	6 6							
low 47.82 47.82 47.82 47.82 82.3 82.3 82.3 82.3 59.0 59.0 59.0 59.0 89.	39.7 89.7 84.6 84.6							
er 5 5 5 4 4 4 2	2 2 7 7							

	CI																
	ирр	100	100	100	100	100	100	100	100	100	100	100	100	100	100	99.9	99.9
	er															3	3
	CI																
lg	Ν	5	5	5	5	19	19	19	19	8	8	8	8	34	34	34	34
Μ	N +	5	5	5	5	19	19	19	19	7	7	7	7	34	34	34	34
	N -	-	-	-	-	-	-	-	-	1*	1*	1*	1*	-	-	-	-
	ТР	1	1	4	3	4	4	6	4	2	2	3	2	6	6	5	5
	FN	4	4	1	2	15	15	13	15	5	5	4	5	28	28	29	29
	PPA, %	20.00	20.00	80.00	60.00	21.0	21.0	31.5	21.0	28.5	28.5	42.8	28.5	17.6	17.6	14.7	14.7
						5	5	8	5	7	7	6	7	5	5	1	1
	lower	0.51	0.51	28.36	14.66	6.05	6.05	12.5	6.05	3.67	3.67	9.9	3.67	6.76	6.76	4.95	4.95
	CI							8									
	uppe	71.64	71.64	99.49	94.73	45.5	45.5	56.5	45.5	70.9	70.9	81.5	70.9	34.5	34.5	31.0	31.0
	r Cl					7	7	5	7	6	6	9	6	3	3	6	6

577 *1 sample was detected as antibody-negative by the Elecsys Anti-SARS-CoV-2 S and the SARS-CoV-2 Rapid Antibody Test.

578 +, positive by the reference test (Elecsys Anti-SARS-CoV-2 S assay); -, negative by the reference test (Elecsys Anti-SARS-CoV-2

579 S assay); CI, 95% confidence intervals; TP, true-positive; FN, false-negative; PPA, positive percent agreement

medRxiv preprint doi: https://doi.org/10.1101/2021.12.17.21267927; this version posted April 4, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

- 580 Figure 1: SARS-CoV-2 Rapid Antibody Test semi-quantitative IgG vs Elecsys Anti-
- 581 SARS-CoV-2 S assay total antibody titer following vaccination with Moderna mRNA-
- 582 1273 (left panel) or Pfizer-BioNTech BNT162b2 (right panel) at least 14 days



583 following second dose



Results from the SARS-CoV-2 Rapid Antibody Test were classified as negative or 586

587 one of the five levels of increasing positivity based upon line intensity (((+)), (+), +)

588 ++ or +++). Maximum value attainable by the Elecsys Anti-SARS-CoV-2 assay was

25,000 U/mL. Higher values are indicated as >25,000 U/mL. Blue = Lot 1; red = Lot 589

590 2; \circ = Evaluator 1; + = Evaluator 2.

- 592 Figure 2: SARS-CoV-2 Rapid Antibody Test semi-quantitative IgM vs Elecsys Anti-
- 593 SARS-CoV-2 S assay total antibody titer following vaccination with Moderna mRNA-
- 1273 (left panel) or Pfizer-BioNTech BNT162b2 (right panel) at least 14 days
 - >25.000 lol e + 0# >25.000 100 4 الە 20.000 20,000 0 0 œ 10.00 00-1 8,000 6,000 5,000 4,000 8,000 Elecsys Anti-SARS-CoV-2 S total artibody tter (U/mL) Elecsys Anti-SARS-CoV-2 S total antibody ther (U/mL HP P 6,000 5,000 00 - . 0 4,000 œ∔ ○⊕ 3.000 3,000 + ten t +0 2,000 2,000 -160 +0 ol d \$ \$ \$ 1,000 800 600 500 400 1,000 800 600 500 400 300 £H +0 +10 0 00| 0++0 o 0+ 300 200 200 100 80 60 50 40 30 100 80 60 50 40 30 20 20 10 10 . ((+)) (+) ++ +++ ((+)) (+) ** +++ SARS-CoV-2 Rapid Antibody Test SARS-CoV-2 Rapid Antibody Test
- 595 following second dose



602

- 603 Figure 3: Elecsys Anti-SARS-CoV-2 S assay total antibody titer over time following
- vaccination with Moderna mRNA-1273 or Pfizer-BioNTech BNT162b2 (second dose)



605

Maximum value attainable by the Elecsys Anti-SARS-CoV-2 assay was 25,000
U/mL. Higher values are indicated as >25,000 U/mL. Blue = mRNA-1273; red =

608 BNT162b2